Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

被引：0
|
作者：
Janne B Kjersem
Tone Ikdahl
Tormod Guren
Eva Skovlund
Halfdan Sorbye
Julian Hamfjord
Per Pfeiffer
Bengt Glimelius
Christian Kersten
Hiroko Solvang
Kjell M Tveit
Elin H Kure
机构：
[1] Institute for Cancer Research,Department of Genetics
[2] Oslo University Hospital,Department of Oncology
[3] Oslo University Hospital,School of Pharmacy
[4] University of Oslo and the Norwegian Institute of Public Health,Department of Oncology
[5] Haukeland University Hospital,Department of Oncology
[6] Odense University Hospital,Department of Radiology, Oncology and Radiation Science
[7] Uppsala University,Department of Oncology and Pathology
[8] Karolinska Institutet,Center for Cancer Treatment
[9] Southern Hospital Trust,undefined
来源：
BMC Cancer | / 12卷
关键词：
Colorectal cancer; LCS6; MiRNA polymorphism; Cetuximab; Oxaliplatin; 5-fluorouracil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin
    Ichikawa, Wataru
    Ooyama, Akio
    Toda, Etsuko
    Sugimoto, Yoshikazu
    Oka, Toshinori
    Takahashi, Takehiro
    Shimizu, Michio
    Sasaki, Yasutsuna
    Hirayama, Renzo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (06) : 794 - 801
  • [32] Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin
    Wataru Ichikawa
    Akio Ooyama
    Etsuko Toda
    Yoshikazu Sugimoto
    Toshinori Oka
    Takehiro Takahashi
    Michio Shimizu
    Yasutsuna Sasaki
    Renzo Hirayama
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 794 - 801
  • [33] Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
    M. Di Bartolomeo
    F. Pietrantonio
    F. Perrone
    K. F. Dotti
    A. Lampis
    C. Bertan
    E. Beretta
    L. Rimassa
    C. Carbone
    P. Biondani
    R. Passalacqua
    S. Pilotti
    E. Bajetta
    Targeted Oncology, 2014, 9 : 155 - 162
  • [34] Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
    Di Bartolomeo, M.
    Pietrantonio, F.
    Perrone, F.
    Dotti, K. F.
    Lampis, A.
    Bertan, C.
    Beretta, E.
    Rimassa, L.
    Carbone, C.
    Biondani, P.
    Passalacqua, R.
    Pilotti, S.
    Bajetta, E.
    TARGETED ONCOLOGY, 2014, 9 (02) : 155 - 162
  • [35] KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
    Zhang, W.
    LaBonte, M. J.
    Lenz, H. -J.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 484 - U267
  • [36] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    L Paré
    E Marcuello
    A Altés
    E del Río
    L Sedano
    J Salazar
    A Cortés
    A Barnadas
    M Baiget
    British Journal of Cancer, 2008, 99 : 1050 - 1055
  • [37] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    Pare, L.
    Marcuello, E.
    Altes, A.
    del Rio, E.
    Sedano, L.
    Salazar, J.
    Cortes, A.
    Barnadas, A.
    Baiget, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (07) : 1050 - 1055
  • [38] Patients With Locally Advanced and Metastatic Colorectal Cancer Treated With Capecitabine Versus 5-Fluorouracil as Monotherapy or Combination Therapy With Oxaliplatin: A Cost Comparison
    Chu, Edward
    Schulman, Kathy L.
    McKenna, Edward F., Jr.
    Cartwright, Thomas
    CLINICAL COLORECTAL CANCER, 2010, 9 (04) : 229 - 237
  • [39] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin? (vol 8, pg 315, 2008)
    Pare, L.
    Marcuello, E.
    Altes, A.
    del Rio, E.
    Sedano, L.
    Barnadas, A.
    Baiget, M.
    PHARMACOGENOMICS JOURNAL, 2009, 9 (03): : 218 - 218
12345